Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedTuberculosis

Implications of edge cases for antimicrobial susceptibility predictions for rifampin, delamanid, and pretomanid with the WHO <i>Mycobacterium tuberculosis</i> mutation catalog.

Microbiology spectrum·

Hermans N, Phelan J, Sorrentino R, Boysen F, Sherry NL, Miotto P, Cirillo DM, Chindelevitch L, Rodwell TC, Barilar I, Niemann S, Andres S, Mischnik A, Horan K, Bond K, Globan M, Rubinstein M, Losev Y, Clark TG, Mitarai S, Iskakova A, Slyzkyi A, Köser CU, Kremer K, Anthony R

DOI
10.1128/spectrum.01821-26
PMID
42644623
PMCID
OpenAlex
Study type
Journal article
Publisher
Publisher unavailable
Article type
journal-article
Integrity
current

Why this research matters now

The WHO mutation catalog is increasingly used for clinical decision-making, and false-resistant predictions for rifampin, delamanid, and pretomanid can lead to inappropriate treatment adjustments, highlighting the need for systematic quality control.

01

Structured evidence summary

Research question

The study examines edge cases in which WHO Mycobacterium tuberculosis mutation catalog grading rules overcall resistance for rifampin, delamanid, and pretomanid.

Study design

Descriptive analysis of three specific edge cases involving WHO catalog grading rules, combining mutation mapping evaluation with sequence assembly approaches.

Population and setting

Mycobacterium tuberculosis sequence data scenarios, including an example from lineage 4.6.1 Uganda genotype strains.

Main findings

Three edge cases were identified: a low-frequency rpoB variant within the RRDR arising from a sequencing artifact; apparent fbiC deletions in a tandem repeat region caused by mapping errors, which assembly showed did not affect the fbiC coding region; and an fbiC frameshift in lineage 4.6.1 Uganda genotype strains with a modest impact on the end of fbiC.

Public-health relevance

The WHO mutation catalog is increasingly used for clinical decision-making, and false-resistant predictions for rifampin, delamanid, and pretomanid can lead to inappropriate treatment adjustments, highlighting the need for systematic quality control.

Important limitations

No explicit limitations are stated in the supplied abstract. This summary is limited to the supplied single-article abstract and metadata and requires review of the original paper for decision-grade interpretation.

GIDS interpretation

The article is relevant to discoverability contexts involving WHO mutation catalog edge cases for rifampin, delamanid, and pretomanid ASPs in M. tuberculosis; this summary does not connect the paper to any live surveillance signal.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 5 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicevaluates interventionstudied population settinguses study design